IBA User Meeting Signals Maturing Proton Therapy Market
Event summary
- IBA hosted its Proteus User Meeting 2026 in Belgium, gathering approximately 250 cancer specialists.
- The meeting marks the 25th anniversary of the first patient treated with IBA’s Proteus® proton therapy system.
- The event included technical workshops covering patient selection, emerging treatments, and system lifecycle management.
- Daphne Haas-Kogan, Radiation Oncologist-in-Chief at Mass General Brigham Cancer Institute and Professor at Harvard Medical School, co-hosted the event.
The big picture
IBA’s dominance in proton therapy positions it to benefit from the growing demand for advanced cancer treatments. The meeting underscores the importance of a collaborative ecosystem for driving innovation and clinical adoption within a specialized, high-capital equipment market. The 25-year milestone highlights the longevity and refinement of the technology, but also the need for ongoing investment to maintain market leadership.
What we're watching
- Market Adoption
- The continued gathering of specialists and focus on clinical practice suggests increasing adoption of proton therapy, but the pace of expansion will depend on reimbursement models and patient access.
- Competitive Landscape
- While IBA is the market leader, the focus on innovation and hardware improvements signals intensifying competition within the proton therapy equipment space, requiring IBA to maintain a technological edge.
- Lifecycle Management
- The emphasis on long-term system lifecycle management indicates that IBA’s future revenue streams will increasingly rely on service contracts and upgrades, rather than solely on equipment sales.
Related topics